August 8th 2023
Almost half of adults surveyed by KFF would be interested in taking a weight-loss drug, including many who say they only want to lose a little weight.
August 3rd 2023
Researchers say capping insulin costs at $35 a month has the potential to lower events and costs related to diabetes, such as amputations, vision loss, and heart attacks.
July 24th 2023
Sara Izadi, Pharm.D., of Capital Rx, talks about Rx Reverse, an integrated clinical program designed to help members reverse diabetes and fight obesity.
July 20th 2023
An analysis by Biosimilars Council has found that the reference product Lantus accounts for 54% of new prescriptions and is 78% of total market volume but demand for the unbranded interchangeable insulin glargine is increasing.
June 29th 2023
Longer-acting growth hormone reduces frequency of injections. It will be available in August.
FDA Approves First Cellular Therapy for Type 1 Diabetes
In two small studies, patients were able to be free from insulin injections for a year or more.
FDA Clears Jardiance and Synjardy for Kids with Type 2 Diabetes
Jardiance and Synjardy are the first SGLT2 inhibitors approved for children with type 2 diabetes.
New Insulin Cap Bill Lauded, But Caution Urged
A bipartisan Senate bill, Affordable Insulin Now Act of 2023, would require plans to cover insulin for no more than $35 per month.
California Selects Generic Company Civica Rx as Insulin Partner
CalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens.
Sanofi Slashes Lantus List Price by 78%
The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance.
Novo Nordisk Cuts Price on Several Insulin Products by 75%
The lower prices will take effect on Jan. 1, 2024, on both pre-filled pens and vials of basal, bolus and pre-mix insulins, including Levemir, Novolin, NovoLog and NovoLog Mix 70/30.
FDA Accepts sNDA for Jardiance in Children 10 to 17 with Diabetes
If approved, Jardiance would be the first SGLT2 inhibitor indicated for this population. A decision is expected in the second quarter of 2023.
Updated: Lilly Cuts Prices of Some Insulins and Caps Out-of-Pocket Costs
The price cuts apply to Lilly’s nonbranded insulin, Humalog, Humulin and its Lantus biosimilar.
FDA Approves New Drug for Type 2 Diabetes
Once-daily, oral SGLT2 inhibitor Brenzavvy has been shown to reduce blood sugar and improve glycemic control.
FDA Accepts Jardiance sNDA for CKD Indication
A phase 3 trial showed that Jardiance reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo. An FDA decision is expected in the second half of 2023.
Study: Medicare Patients to Benefit from $35 Insulin Cap
The Inflation Reduction Act’s cap on out-of-pocket costs for insulin is likely to improve outcomes for almost half of Medicare’s insulin users.
FDA Approves Rybelsus for First-line Treatment of Diabetes
This update removes a previous limitation that it could not be used as the first therapy.
Major Diabetes Medications in Short Supply
Lilly’s first-in-class medicine that activates both the GLP-1 and GIP receptors, Mounjaro, is the latest to be included on the FDA’s drug shortages list because of high demand.
Prescryptive Health Partners with Lilly for Insulin Program
Prescryptive will offer a subscription-based program for employers that aims to provide a more predictable benefit for companies and their employees.
FDA Approves Second Interchangeable Lantus Biosimilar
Lilly’s Rezvoglar is a long-acting human insulin analog. It follows Semglee as a biosimilar that can be substituted for Lantus for both adults and children with diabetes.
FDA Approves First Drug that Delays Diabetes
Tzield addresses the underlying cause of the disease, where the immune system destroys the insulin producing cells in the pancreas. It will be available by the end of the year with a wholesale acquisition cost of $13,850 per vial.
Battery Issues Affect Omnipod Dash Personal Diabetes Managers
Omnipod DASH PDMs are at increased risk of malfunction if overcharged beyond the maximum battery voltage.
Wellcare Expands Medicare Drug Coverage, Adds Amazon as Preferred Pharmacy
A new formulary design will be offered on the Value Script and Value Plus plans; it will contain medications used to treat diabetes and will cost only $11 per 30-day supply.
FDA Expands Use of Omnipod 5 for Younger Children
Omnipod 5 is now available through retail pharmacies, as well as specialty and mail-order pharmacies.
CivicaScript Launches Generic Abiraterone
Abiraterone is used together with prednisone to treat patients with metastatic prostate cancer.
Senate Passes Bill that Caps Insulin at $35 for Medicare Beneficiaries
The Inflation Reduction Act also allows Medicare to negotiate prices on some drugs and caps out-of-pocket costs for Medicare beneficiaries.
Optum to Offer $35 Insulin to Those without Insurance
Optum has teamed up with Sanofi to provide savings cards for six insulins through the Optum Store.
FDA Extends Review of Diabetes Therapy Teplizumab
The new PDUFA date is Nov. 17, 2022. If approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes.
Sanofi Lowers Insulin Price
Sanofi has lowered the out-of-pocket cost for those without insurance of its insulins to $35 for a 30-day supply through the company’s savings program.
FDA Updates Safety Label of Byetta
Byetta is used to control blood sugar in patients with diabetes. A new warning includes the risk of gallstones and gallbladder inflammation.
Study: Medicare Part D Enrollees’ Spending for Insulin Increased
If insulin copays were capped at $35, Part D enrollees would save 29% on average, according to new analysis from Kaiser Family Foundation.
FDA Okays Lilly’s Novel Diabetes Drug
Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control.
FDA Approves Higher Dose of Ozempic
Ozempic is now available in three doses to improve blood sugar in people with type 2 diabetes.
Civica’s Allan Coukell Talks about Its Insulin Program
Allan Coukell, Civica’s senior vice president of public policy, discusses how the generic manufacturer is disrupting the market for insulins.
Civica Plans to Sell Lower-Cost Insulins
Once approved, the insulins will be available to patients for no more than $30 per vial.
2 Clarke Drive Cranbury, NJ 08512